12:00 AM
 | 
Jun 09, 2014
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Supernus, United Therapeutics sales and marketing update

United Therapeutics launched Orenitram treprostinil ER in the U.S. to treat pulmonary arterial hypertension (PAH). A wholesale acquisition cost for 100 tablets is $487.50 for the 0.125 mg strength, $975 for the 0.25 mg strength, $3,900 for...

Read the full 173 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >